Jeff Yass’s Rapport Therapeutics RAPP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$529K Buy
15,746
+7,491
+91% +$323K ﹤0.01% 9611
2026
Q2
$344K Sell
8,255
-7,417
-47% -$273K ﹤0.01% 10753
2026
Q1
$490K Buy
15,672
+5,464
+54% +$154K ﹤0.01% 9716
2025
Q4
$310K Sell
10,208
-10,935
-52% -$303K ﹤0.01% 9870
2025
Q3
$628K Sell
21,143
-3,741
-15% -$66.7K ﹤0.01% 8448
2025
Q2
$283K Buy
24,884
+413
+2% +$4.38K ﹤0.01% 10484
2025
Q1
$245K Buy
+24,471
New +$318K ﹤0.01% 10507

Other funds holding RAPP

Jeff Yass's RAPP Position: Q3 2026 in Review

Jeff Yass increased its Rapport Therapeutics (RAPP) stake by 91% in Q3 2026, buying an estimated $323K and bringing the position to 15,746 shares worth $529K. The position accounts for ﹤0.01% of the portfolio, ranked #9611.

Jeff Yass first reported a position in RAPP in Q1 2025 and has held it in 7 quarters since. The position peaked at $628K in Q3 2025. 167 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.

  • Jeff Yass held 15,746 shares of Rapport Therapeutics worth $529K as of Q3 2026.
  • Jeff Yass bought 7,491 Rapport Therapeutics shares in Q3 2026, an estimated $323K.
  • Rapport Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #9611 holding.
  • Jeff Yass first reported a position in Rapport Therapeutics in Q1 2025 and has held it in 7 quarters since.
  • Jeff Yass's Rapport Therapeutics position peaked at $628K in Q3 2025.
  • 167 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.